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Abstract: Uveitis can be a sight-threatening eye disease with significant morbidity. 
  Corticosteroids remain the mainstay of treatment of uveitis and provide an effective treatment 
against ocular inflammation. However, the various modes available for corticosteroid drug 
delivery can carry significant ocular and systemic side effects which can limit their use in the 
treatment of uveitis. In an effort to avoid the damage to ocular structures that can ensue with 
recurrent episodes of ocular inflammation, the side effects associated with systemic steroids, 
and the need for repeated administration of both topical and locally injected corticosteroids, 
sustained-release intraocular corticosteroid implants have been developed. The dexamethasone 
(DEX) drug delivery system (Ozurdex®; Allergan Inc, Irvine, CA), is a biodegradable intravitreal 
implant. This implant has been shown to be effective in the treatment of macular edema and 
noninfectious posterior uveitis and has been approved by the FDA for these entities. This review 
will highlight the current methods available for corticosteroid delivery to the eye with a particular 
emphasis on the DEX intravitreal implant and the evidence currently available for its use in 
noninfectious uveitis.
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Introduction
Uveitis refers to inflammation of the uveal tissues, including the iris, ciliary body, and 
choroid, however, other intraocular structures such as the retina and optic nerve may 
be involved. Uveitis is a leading cause of visual impairment and accounts for 30,000 
new cases of legal blindness annually in the Western world.1 Although uveitis can 
affect all age populations, the mean age of patients with uveitis is 40 years old, which 
creates a large impact on society and healthcare.
The Standard Uveitis Nomenclature (SUN) criteria were developed to create a 
classification scheme that categorizes uveitis based on the primary anatomical location 
of inflammation.2 Under this method of classification uveitis can be divided into 
anterior, intermediate, and posterior. Anterior uveitis which can involve the iris, ciliary 
body, cornea, and sclera is the most common type of uveitis and accounts for approxi-
mately 50%–60% of all cases of uveitis in tertiary care centers.1 Most cases of anterior 
uveitis are noninfectious but the definitive etiology of anterior uveitis can only be 
found in 65% of patients, with the remaining cases regarded as “idiopathic”.1
Intermediate uveitis is used to denote intraocular inflammation involving the 
anterior vitreous and pars plana. Intermediate uveitis is the least common type of 
uveitis and has been found to account for 3%–17% of uveitis around the world.1 Given 
its more posterior location, patients with untreated intermediate uveitis are at increased Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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risk for developing significant and sometimes permanent 
vision loss from cystoid macular edema.3
Posterior uveitis involves the retina and choroid but can 
also affect the optic nerve. It accounts for 10%–40% of 
uveitis cases, however it accounts for more visual loss than 
other forms of uveitis. Vision loss can be caused by cystoid 
macular edema, retinal detachment, subretinal fibrosis, or 
optic nerve damage.1,3 Up to 50% of patients with posterior 
uveitis have an associated systemic disease.1
Standardization of the criteria for classifying uveitis by 
location of active inflammation has had an important impact 
not only on maintaining a consistent method of comparing 
clinical data from different research centers, but also on 
improving our understanding of treatment modalities and 
response to treatment. Numerous therapies exist for uveitis, 
but the most commonly utilized treatment is corticosteroids. 
This review will highlight the current methods available for 
corticosteroid delivery to the eye with a particular emphasis 
on the dexamethasone intravitreal implant and the evidence 
available for its use in noninfectious uveitis.
An overview of corticosteroid 
therapy in uveitis
Corticosteroids are the first-line therapy for noninfectious 
uveitis. The anti-inflammatory effects of corticosteroids are 
mediated by the cytosolic glucocorticoid receptors which 
increase expression of anti-inflammatory proteins.4 Gluco-
corticoids can also inhibit the release of proinflammatory 
cytokines both systemically and in the eye. There are different 
forms of administration of corticosteroids for the treatment 
of ocular inflammation: topical, local, and   systemic. The use 
of topical corticosteroids for the treatment of anterior uveitis 
was first described in the 1950s.5 Since then, topical corti-
costeroids have become the primary form of treatment of 
anterior uveitis. The advantages of topical administration of 
steroids to the eye are numerous. Topical steroids provide 
direct delivery to the eye with excellent penetration into the 
anterior chamber. Given the relative ease of administration, 
topical steroids can be given at frequent intervals depending 
on the degree of active anterior chamber inflammation. 
Finally, topical steroids have minimal systemic absorption 
thereby reducing risk of systemic side effects.1,6 However, 
chronic administration of steroids, as is the case for any local 
steroid administration, can have significant local side effects, 
including cataract formation and increased intraocular 
pressure (IOP) with possible development of glaucoma.6 An 
additional limitation is that topical administration of corti-
costeroids does not penetrate ocular structures to adequately 
treat posterior forms of uveitis. Finally, it can be cumbersome 
for patients to administer frequent topical steroid drops 
especially on a long-term basis.
Local injection of corticosteroids is an important modality 
in the treatment of both intermediate and posterior uveitis. 
Corticosteroids such as methylprednisolone and triamcino-
lone can be administered to the eye either through a periocular 
sub-Tenon’s injection, transeptal injection, or directly into 
the vitreous cavity. Direct administration of steroids to the 
eye has significant benefits in the delivery of medication to 
the posterior segment and proximity to more sensitive ocular 
structures such as the macula and optic nerve. Corticosteroid 
injections provide higher therapeutic concentrations in the 
posterior pole for adequate treatment of posterior segment 
inflammation.4 There is minimal systemic absorption follow-
ing local administration of steroids, thereby avoiding the 
usual side effects of systemic corticosteroids.7 Local admin-
istration of corticosteroids is beneficial in patients who have 
unilateral ocular disease where systemic corticosteroids may 
not be desirable. However, the half-life of local corticosteroid 
administration ranges from 3–4 months and patients may 
require repeated injections.3 As the intraocular steroid con-
centration declines between injections, patients are poten-
tially at increased risk of visual loss in between injections 
from recurrent inflammation. Finally, there are various risks 
to periocular steroid injection including inadvertent globe 
penetration, extraocular muscle injury, ptosis, and local skin 
depigmentation.1 The risks of intravitreal injection include 
vitreous hemorrhage, retinal detachment, and   endophthalmitis. 
Both periocular and intravitreal corticosteroid administration 
also carry the common side effects seen with topical steroids: 
cataract formation and elevation of IOP. Both of these side 
effects are higher with intravitreal injections than with perio-
cular and topical steroid administration.7 Studies have dem-
onstrated that the risk of developing a cataract after 
intravitreal steroid injection is five-fold higher than the gen-
eral population.8 Elevated IOP can be seen in up to 43% of 
patients after intravitreal steroid injections with a mean eleva-
tion of 11 mmHg.8,9 In patients with elevated IOP, 51% 
require treatment with topical IOP-lowering drops.8
Systemic administration of steroids is generally the first-
line treatment for posterior noninfectious uveitis.3 Oral ste-
roids are the most common route of systemic administration, 
but intravenous administration of steroids may be indicated 
in patients with sight-threatening inflammation. For patients 
with significant posterior segment inflammation, oral 
  prednisone at 1 mg/kg/day can be initiated and then tapered 
as inflammation improves. Despite having significant Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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anti-inflammatory effects in the eye, systemic administration 
of steroids, especially when used chronically, can have sig-
nificant ocular and systemic side effects. Because uveitis is 
very often a recurrent disease, many patients may require 
prolonged treatment. The side effects of systemic steroids 
are numerous and include glucose intolerance, osteopenia, 
avascular necrosis, bone marrow suppression, gastric ulcer-
ation, weight gain, and psychological disturbances.1,10 In 
addition, as with all modes of steroid administration, patients 
on oral steroids are at increased risk of developing cataracts 
and elevated IOP.
intravitreal implants
Long-term control of intraocular inflammation with minimal 
relapses portends a better visual prognosis for patients when 
compared to patients with repeated episodes of intraocular 
inflammation.10 A recent development in local drug delivery 
is surgically implantable steroid devices. These novel 
implants provide long-term, slow release of steroids to the 
eye providing sustained control of intraocular inflammation. 
These devices were developed based on the ganciclovir 
intravitreal implants that were used for the treatment of 
cytomegalovirus retinitis.11 Initial studies of implantable 
intravitreal devices used dexamethasone as the preferred 
steroid component, however initial animal studies demon-
strated a short half-life with dexamethasone.12 Instead, fluo-
cinolone acetonide which has 1/20 the solubility of 
dexamethasone in aqueous and high potency, was used in a 
small sustained release implant.13 A fluocinolone acetonide 
(FA) intravitreal implant (Retisert; Bausch & Lomb, 
  Rochester, NY) was the first FDA-approved implantable 
device for the treatment of severe, noninfectious, posterior 
uveitis.11,14 This device is surgically placed in the vitreous 
cavity at the pars plana. Initial human studies revealed sig-
nificant control of intraocular inflammation with the 
FA implant.15 Patients with noninfectious posterior uveitis 
treated with the implant had significantly decreased recur-
rences of inflammation, from a 62% recurrence rate pre-
treatment to 4%, 10%, and 20% recurrence rates at 1, 2, and 
3 years following implantation; recurrence rates of inflam-
mation in eyes receiving the FA implant were significantly 
lower than in fellow nonimplanted eyes.15,16 The FA implant, 
which contains 0.59 mg of fluocinolone acetonide, slowly 
releases corticosteroid over the course of 30 months.16 This 
sustained release provides significantly prolonged anti- 
inflammatory effects with the rare need for additional local 
therapy. If inflammation recurred after the 30 month time 
point, a second FA implant could be placed adjacent to the 
original implant along the pars plana.17 This tandem place-
ment avoids the need to remove the original implant which 
has an increased risk of vitreous or retinal hemorrhage, retinal 
traction, and possible development of retinal detachment.
Complications of the fluocinolone 
acetonide implant
The ocular complications of all corticosteroids (both local 
and systemic) are the same and have been discussed. These 
side effects are directly related to the strength of the steroid 
and its effective ocular penetration. Rates of adverse ocular 
side effects such as cataract formation and elevated IOP are 
higher with fluocinolone acetonide when compared to dex-
amethasone or triamcinolone acetonide.18,19 It is well estab-
lished that corticosteroids induce molecular changes in the 
trabecular meshwork and lens that can then lead to steroid-
induced ocular hypertension and cataract formation. 
  However, currently there is no adequate measure to rank 
corticosteroids by rate of adverse events, including gluco-
corticoid activity, aqueous solubility, or pharmokinetics.20   
To determine whether adverse effects may be related to 
partitioning of drug molecule into the trabecular meshwork 
and lens, a recent study by Thakur et al analyzed the lipophi-
licity of these corticosteroids and the relationship to ocular 
tissue partitioning in bovine and human tissue models.21 This 
study demonstrated that the lipophilicity of corticosteroids 
can be directly related to the degree of ocular side effects in 
animal models. The more lipophilic corticosteroid, fluocino-
lone acetonide, exhibits higher partitioning in the trabecular 
meshwork and lens in both bovine and human eye tissue 
which may provide one explanation why the incidence of 
side effects in prior clinical trials is highest with fluocinolone 
acetonide when compared to triamcinolone or   dexamethasone. 
Although this study offered some supportive molecular 
evidence for the rate of ocular adverse effects seen in the 
various ocular corticosteroid preparations, there are certainly 
other characteristics such as length of implant duration and 
dose that must also be considered and have not been system-
atically studied.
Significant ocular adverse effects have been documented 
with the FA intravitreal implant. The FA implant has con-
sistently shown marked induction of cataract formation; 
long-term clinical studies revealed that within 3 years of 
implantation, 100% of patients required cataract   extraction.15 
In addition, at 34 weeks 51.1% of eyes with the implant 
required more topical pressure-lowering agents than 
  nonimplanted eyes and 78% of implanted eyes required 
pressure lowering drops by 3 years postimplantation. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Approximately 40% of patients with the FA implant 
required glaucoma filtering surgery within 3 years following 
implantation due to uncontrolled IOP elevations.18 Unlike 
topical and systemic steroids which can be discontinued in 
the setting of significant ocular morbidity, the FA implant 
is not biodegradable and must be surgically removed if 
clinically indicated in the setting of significant adverse 
effects. In addition, unlike periocular and intravitreal steroid 
injections which generally have a half-life of 4 months or 
less, the FA implant has effects for up to 2.5–3 years. 
Patients who will be undergoing placement of the FA 
implant should be aware and understand the possible long-
term implications of treatment with additional medications 
(anti-glaucoma medications) and surgery (both for cataract 
formation and glaucoma). Other less common side effects 
of the FA implant which were noted in clinical trials 
included   hypotony (6.1%), retinal detachment (2.9%), 
endophthalmitis (0.4%), and need for explantation at 2 years 
in 3.6% of cases for the following reasons: postoperative 
hypotony, uncontrollable IOP, endophthalmitis, and an 
unrelated case of intraocular lymphoma.
Intravitreal dexamethasone  
drug delivery system
Design and pharmacology
Dexamethasone is a widely used corticosteroid for the treat-
ment of systemic inflammatory conditions. Dexamethasone 
is five times more potent than triamcinolone acetonide, which 
is commonly used for periocular injections (Kenalog®) and 
intravitreal injections (Triesence®). In addition, given its 
hydrophilicity, it allows for higher vitreous concentration 
than triamcinolone acetonide. The drawback of developing 
a topical or periocular dexamethasone formulation for ocular 
inflammatory disease has been the requirement of substan-
tially higher concentrations of the drug to cross the cellular 
junctions at the ocular surface and through the blood–retinal 
barrier which can cause significant toxicity.19 Dexamethasone 
has been used as an intravitreal injection, but it has been 
shown to be significantly shorter acting in the vitreous than 
triamcinolone acetonide and fluocinolone acetonide, with a 
half-life of between 3–6 hours (Table 1).1,20 This brief half-
life precludes the use of dexamethasone injections as a long-
term treatment for ocular inflammation. These shortcomings 
have been addressed with the development of a biodegradable 
dexamethasone drug delivery system (Ozurdex®, Allergan, 
Inc, Irvine, CA) (Figure 1).
The idea of a creating a biodegradable polymer matrix 
to be used as a sustained drug delivery system in humans 
has been attaining significant importance in biomedical 
research. These polymers have been used to create nano-
particles and microparticles for systemic drug delivery that 
can be targeted to specific human tissues such as the heart, 
or have novel peptide coatings which can be directed 
towards human malignancies such as intracranial tumors.22 
Having a biodegradable implant as a platform for drug 
delivery is ideal, particularly for ocular tissues, given the 
small size of the organ and significant risk in placing and 
removing permanent implants as was discussed with the 
FA implant. The sustained-release dexamethasone drug 
delivery system is made of a solid biodegradable polymer 
composed of apolylactic acid-co-glycolic acid (PLGA) 
matrix.23 The PLGA polymer matrix dissolves completely 
in vivo into its components, lactic acid and glycolic acid. 
These products are in turn converted to carbon dioxide and 
water which can be easily eliminated by ocular tissue.24,25 
The biodegradable matrix is saturated with 0.7 mg of 
  dexamethasone. As the polymer dissolves, dexamethasone 
is slowly released into its target tissues, the vitreous and 
retina. The implant was not only developed to be biodegrad-
able but was also designed to be administered as an office-
based procedure. The implant can be injected through a 
22-gauge injecting applicator through the pars plana similar 
to other intravitreal injections. This application is performed 
under a sterile technique via a bi-planar injection.
Figure 1 Dexamethasone intravitreal implant and injector (Ozurdex®, Allergan, inc, 
irvine, CA).
Table 1 Pharmacokinetics of intraocular steroids
Steroid Water 
solubility 
(μg/mL)
Half-life 
(solubilized)a
Relative 
potency
Triamcinolone acetonide 21 18 days 1
Fluocinolone acetonide 50 Data not available 0.4×
Dexamethasone 100 3.5 hours 3–5×
Note: aHalf-life in human vitreous.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Pharmacokinetics/pharmacodynamics  
of dexamethasone implant
Chang-Lin et al recently determined the pharmokinetics 
and pharmacodynamics of the sustained-release dexame-
thasone drug delivery system by using mass spectrometry 
and expression of the dexamethasone-sensitive gene cyto-
chrome P450 A38 (CYP3A8), which is a marker of dex-
amethasone biological activity in the retina.24 Thirty-four   
male monkeys received bilateral 0.7 mg dexamethasone 
implants; three animals served as controls. Samples of 
blood, vitreous, and retina were retrieved up to 270 days 
(9 months) after initial implantation. Dexamethasone was 
detectable in retina and vitreous for 6 months after admin-
istration with peak concentrations during the first 2 months. 
The peak concentration of dexamethasone in the retina 
reached 1110 ± 284 ng and 213 ± 49 ng/mL in the vitreous 
at 2 months (day 60). There was minimal systemic absorp-
tion with a peak concentration of 1.11 ng/mL in the serum 
at 2 months. Following the first 2 months there was a steady 
decline in steroid concentration from month 2 to month 3, 
after which a second steady state was achieved and main-
tained until month 6. The CYP3A8 expression increased 
more than three-fold in eyes that had received the implant 
compared to control eyes and this increased expression 
was sustained for 6 months. This study confirmed what was 
noted in clinical trials: the dexamethasone implant has 
persistent effects on target tissue up to 6 months after 
implantation. In addition, it was noted that the initial burst 
release of dexamethasone from the implant upon adminis-
tration reaches an initial steady state at therapeutic concen-
tration, which is then followed by decline to a second steady 
state with lower sustained release of   dexamethasone. These 
results also confirmed the low risk of systemic absorption 
of medication.
Clinical efficacy, safety, and 
tolerability of dexamethasone 
intravitreal implants
Preclinical studies: animal models
A non-biodegradable dexamethasone implant was first 
developed by Cheng et al for the treatment of experimental 
uveitis.26 Implantable pellets contained 5 mg of dexametha-
sone and were coated in polymers to ensure sustained release 
of medication. These devices were implanted in rabbit eyes 
via a 3-mm sclerotomy site 3 mm from the limbus. The device 
was inserted into the vitreous and sutured into place, with 
fellow eyes receiving implantation of polymer alone and 
used as controls. The rabbits were induced to have two epi-
sodes of severe panuveitis separated by 2 weeks. The implants 
were explanted at 99 days and found to have 30% of the drug 
remaining. Electroretinography (ERG) performed showed 
significant depression in untreated eyes compared to treated 
eyes. In addition, clinical findings noted significantly less 
inflammation in treated eyes when graded by two masked 
observers. The authors concluded that intravitreal implanta-
tion of a sustained-release dexamethasone device provided 
effective suppression of severe ocular inflammation for more 
than 3 months and allowed for prevention of ocular compli-
cations from recurrent inflammatory episodes in animal 
models. This study provided the initial support for the use 
of dexamethasone as a treatment for posterior uveitis.
early clinical trials: treatment  
of macular edema
Initial clinical studies were performed to evaluate the safety 
and efficacy of the dexamethasone implant in patients with 
persistent macular edema. Subsequent studies would be 
performed to evaluate use in posterior uveitis. Kuppermann 
et al performed a multi-center, Phase II trial enrolling patients 
with persistent macular edema.27 The inclusion criteria 
included persistent clinically significant macular edema for 
90 days or more despite laser and medical treatment. The 
underlying cause of macular edema could be diabetic retin-
opathy, retinal vein occlusion, postoperative complications 
such as Irvine–Gass syndrome, or uveitis. A total of 
315 patients were enrolled with best-corrected visual acuity 
(BCVA) of 20/40 to 20/200 in the study eyes. The patients 
were randomized to observation, treatment with surgically 
implanted dexamethasone implant of two different concentra-
tions, 0.35 mg and 0.7 mg in a 1:1:1 ratio. The primary 
outcome measure was improvement of BCVA of ten or more 
letters at 90 days. A significantly greater proportion of 
patients who received either dexamethasone implant achieved 
ten or more letters of visual improvement 90 days after 
implantation (24% in 0.35 mg group and 35% in the 0.7 mg 
group) than control eyes (13%). In addition, patients receiv-
ing the higher concentration implant had a greater rate of 
visual improvement (35% in 0.7 mg implant vs 24% in 
0.35 mg implant). These results were similar in all patients 
despite the etiology of their macular edema. Patients were 
observed a total of 180 days and continued to show a statisti-
cally significant improvement in BCVA in the 0.7 mg dex-
amethasone implant group compared to the control group. 
11% of patients treated with the dexamethasone implant had 
an increase in IOP of .10 mmHg or higher compared to the Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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control group (2%). None of these patients required laser or 
surgical intervention for IOP control and were managed 
successfully with medication. Finally, there was no signifi-
cant difference in the number of reported cataracts among 
the different study groups. The authors concluded that the 
dexamethasone implant was well tolerated and had a satisfac-
tory safety profile.
Further subset analysis was performed examining effec-
tiveness of treatment with the dexamethasone implant in 
patients with macular edema from Irvine–Gass syndrome 
and uveitis.28 This analysis confirmed that patients with 
persistent macular edema from these entities had a significant 
improvement in BCVA at 90 days with the dexamethasone 
implant. It was found that 41.7% of patients in the 0.35 mg 
group and 53.8% of patients in the 0.7 mg group had a ten-
letter or more improvement in BCVA (observation was 
14.3%). Furthermore, a 15-letter improvement in BCVA was 
achieved in 53.8% of patients receiving the 0.7 mg dexam-
ethasone implant. These findings were supported by a 
decrease in fluorescein leakage in treated patients compared 
to control patients. The adverse effects in this subgroup 
analysis of IOP increase and cataract formation were equiva-
lent to the adverse events in the overall study.
The findings of this earlier study were confirmed with 
a multi-center, randomized, controlled clinical trial compar-
ing 0.7 mg dexamethasone implant with sham in eyes with 
macular edema associated with retinal vein occlusion.29 
A total of 1267 patients with vision loss from macular 
edema secondary to a retinal vein occlusion were random-
ized 1:1:1 ratio to either sham procedure or treatment with 
dexamethasone intravitreal implant at 0.35 mg dose and 
0.7 mg dose. The study demonstrated that the percentage 
of eyes achieving 15-letter improvement was significantly 
greater in the both dexamethasone treated groups compared 
to sham. The greatest response was seen at day 60 in the 
0.7 mg implant group with 29% of patients achieving 
15-letter improvement.   Significant adverse events experi-
enced in the dexamethasone implant treatment groups were 
eye pain, ocular hypertension, and anterior chamber cellular 
reaction. There was no statistically significant increase in 
cataract formation in the treated group. 16% of implanted 
eyes had an increase in IOP that was greater than 15 mmHg. 
Most of these episodes of ocular hypertension were transient 
and there was no difference in IOP elevation between sham 
and treatment groups at 180 days. However, unlike the 
previous clinical trials, where no eyes required surgical or 
laser treatment for elevated IOP, five eyes in the dexametha-
sone implant groups (three in the 0.7 mg group and two in 
the 0.35 mg group) required a procedure to lower pressure. 
The authors cautioned that one of these eyes required the 
procedure for neovascular glaucoma and not for steroid- 
induced glaucoma. They concluded that the dexamethasone 
implant is a therapeutic alternative for patients with vision 
loss due to retinal vascular occlusion-induced macular 
edema. This study led to FDA approval of the dexametha-
sone implant for the treatment of macular edema associated 
with retinal vein occlusion.
Dexamethasone intravitreal implant for 
the treatment of uveitis: clinical trials
More recent clinical studies have focused on the use and 
safety of the dexamethasone implant as monotherapy for the 
treatment of noninfectious intermediate and posterior 
uveitis.30 Lowder et al evaluated the efficacy of two doses of 
dexamethasone (DEX) intravitreal implant in patients diag-
nosed with noninfectious intermediate or posterior uveitis.30   
Inclusion criteria included patients with a vitreous haze score 
greater than +1.5 (on a scale of 0–4) and a BCVA of 20/32 
to 20/630. Patients were allowed to use certain topical and 
systemic medications during the trial if they had been stable 
on the medication prior to randomization. Important exclu-
sion criteria included prior unresponsiveness to corticoster-
oids, glaucoma, ocular hypertension, a known history of 
corticosteroid-induced ocular hypertension, or uncontrolled 
systemic disease. Patients with any known prior use of an 
intravitreal device (dexamethasone or fluocinolone acetonide) 
were excluded. A total of 229 patients were randomized in 
1:1:1 ratio to receive sham procedure or treatment with 
dexamethasone implant (either 0.35 mg or 0.7 mg). 
  Eighty-one percent of patients in the study had intermediate 
uveitis. Patients were observed for 26 weeks for therapeutic 
effect and safety profile. The main outcome measure was the 
percentage of patients with vitreous haze score of 0 at 
8 weeks. The proportion of patients with vitreous haze score 
of 0 at 8 weeks was 47%, 36%, and 12% for the 0.7 mg 
dexamethasone implant, the 0.35 mg implant, and the sham 
group, respectively. The response peaked at week 8 but was 
maintained for up to week 26. Although not used as a main 
outcome measure, BCVA was significantly improved by 
2–6-fold greater in the dexamethasone treated eyes than the 
sham group throughout the study period. The mean decrease 
from baseline central macular thickness on ocular coherence 
tomography (OCT) was also significantly greater in 
the dexamethasone treated groups compared to the sham 
group at 8 weeks. Less than 10% of eyes had an IOP of 
25 mmHg or greater. Throughout the duration of the study, Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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23% of eyes in the 0.7 mg DEX implant group required IOP-
lowering medications. Most patients were either observed or 
treated with 1 IOP-lowering topical medication. No eyes 
required surgical or laser therapy for elevated IOP. Cataract 
formation was reported as an adverse event in 15% of eyes 
in the 0.7 mg DEX implant group, 12% of eyes in the 0.35 mg 
DEX implant group, and 7% in the sham group. These dif-
ferences were not statistically significant. Only one eye in 
the DEX implant-treated group required cataract surgery at 
the end of the 26-week study. Other adverse effects included: 
conjunctival hemorrhage, ocular discomfort, eye pain, and 
iridocyclitis. The between groups analysis for adverse effects 
showed no statistically significant difference between treated 
(DEX implant) and nontreated eyes (sham). There were no 
systemic side effects noted in the DEX implant groups. The 
authors concluded that a single dose of the DEX implant was 
well tolerated in patients with noninfectious posterior uveitis 
with significant improvement in intraocular inflammation 
and visual acuity at 26-week follow-up. The 0.7 mg DEX 
implant demonstrated greater efficacy than the 0.35 mg 
implant with a similar safety profile.
Advantages and disadvantages  
of the dexamethasone intravitreal implant
The use of the DEX intravitreal implant has shown significant 
promise for the treatment of macular edema and more 
recently noninfectious intermediate and posterior uveitis.
It is difficult to compare the efficacy and safety profile 
of the DEX intravitreal implant with other sustained-release 
corticosteroid implants, specifically the FA implant, because 
there are currently no randomized controlled trials to 
compare these devices (Table 2). However, in terms of 
outcomes of BCVA, the improvement of 15 letters or more 
in the FA implant was 21% at 34 weeks. In comparison, 
38% of eyes attained 15-letter improvement in the DEX 
implant study at 26 weeks. These findings could indicate an 
improved response in terms of visual outcomes with the 
DEX implant in comparison to the FA implant although it 
is difficult to draw conclusions given the different half-lives 
of the two implants. It is also difficult to compare adverse 
effect outcomes without a head-to-head randomized control 
trial given the different pharmacokinetic properties and 
duration of effect of the two corticosteroid implants. There 
is no comparative data analyzing secondary adverse effect 
outcomes at 6 months in patients who have received an FA 
implant. Given the available data, the FA implant has sig-
nificant ocular adverse outcomes requiring additional eye 
surgery for the management of cataracts and glaucoma after 
30 months. These findings are in comparison to the DEX 
implant data where few patients required additional ocular 
surgery for the management of adverse effects after 
6 months. As previously discussed it may also be a result of 
the lipophilicity of the corticosteroid used; FA has greater 
portioning into the lens and trabecular meshwork in com-
parison to dexamethasone and this may account for its higher 
side-effect profile.21 Longer duration of exposure of ocular 
structures to steroids may also play a role in adverse effects 
and the safety profile of different steroid moieties may also 
be time dependent. However, chronic ocular inflammation 
may require repeated DEX implantation. Long-term data is 
necessary and further longitudinal studies on the DEX 
implant need to be performed in order to be able to effec-
tively compare adverse effects to other longer-acting steroid 
implants.
There are many advantages to the DEX implant system 
in comparison to other steroid implants. First, the biodegrad-
able matrix used in the DEX implant in comparison to the 
surgically implanted polymer in the FA implant is of major 
importance. The biodegradable polymer provides significant 
clinical benefit in terms of ease of sequential implants without 
the need to surgically remove older devices. Second, the 
platform for delivery has been devised so that it can be per-
formed in an outpatient setting as a more routine intravitreal 
injection as opposed to a surgical procedure which significantly 
Table 2 Comparison of intravitreal implants for the treatment of noninfectious uveitis
0.59 mg fluocinolone acetonide  
(FA) implant
0.7 mg dexamethasone 
(DEX) implant
Administration Operating room Office-based
Matrix Non-biodegradable Biodegradable
Duration of effect 30 months 6 months
improvement of .15 letters (% eyes) 21% by week 34 38% by week 26
Rescue medications (% eyes) 25.4% by week 34 22% by week 26
Glaucoma surgery (% eyes) 30.6% by month 24 0.5% by month 6
Cataract surgery (% eyes) 89.4% by month 24 
100% by month 30
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Dovepress 
Dovepress
1620
Hunter and Lobo
lowers the cost of implantation. Finally, the cost of the DEX 
implant system is significantly lower than the cost of the FA 
implant by approximately 65%. This cost approximation also 
does not take into consideration the additional costs of sec-
ondary surgeries such as cataract surgery and glaucoma filter-
ing procedures that may be necessary in a large portion of the 
FA implant patient population. However, the DEX implant 
system may require multiple implantations per year which 
can escalate its cost. Again, further longitudinal studies on 
the DEX implant need to be performed to be able to effectively 
compare the cost-benefit ratio when compared to other longer-
acting steroid implants.
Future applications
More recently, animal studies have been used to evaluate the 
use of a sustained dexamethasone implant for the treatment 
of experimental anterior and intermediate uveitis.31 Ghosn 
et al assessed the efficacy of the implant in a rabbit model 
of anterior and intermediate uveitis. Inflammation was 
induced using unilateral injection of Mycobacterium 
  tuberculosis H37Ra antigen in preimmunized rabbits.31 
Four days after induction of inflammation, the rabbits 
received an intravitreal dexamethasone device or underwent 
sham   procedure. Clinical and histopathological signs were 
assessed at 13 days. In addition, inflammatory markers were 
measured in the iris and ciliary body at 21 days. The authors 
found that both clinical and histopathological signs of anterior 
and intermediate uveitis were significantly decreased in eyes 
that had received the implant compared with sham eyes. 
Inflammatory cytokines were also significantly decreased in 
the iris and ciliary body of eyes that had been treated, indicat-
ing a reduced intraocular inflammatory response. The authors 
concluded that posterior drug delivery of a sustained release 
dexamethasone implant also achieves therapeutic levels of 
drug in the anterior chamber and pars plana. Further clinical 
studies are needed to evaluate safety and efficacy in treating 
these entities in humans.
Other future considerations in understanding the role of 
inflammation in eye disease are the use of corticosteroid 
implants in patients with age-related macular degeneration 
(AMD). A study involving use of the DEX implant in patients 
with AMD was performed to evaluate its benefits as adjunc-
tive therapy to ranibizumab for the treatment of choroidal 
neovascularization in AMD.32 In a randomized, controlled 
trial of 243 eyes, there was a significant increase in the time 
between doses of “as needed” injections of ranibizumab with 
longer ranibizumab injection-free intervals in patients who 
received the DEX implant. In addition, the authors found that 
addition of the DEX implant increased the percentage   
of eyes with retinal thickness ,250 µm. Adverse effects were 
similar to those seen in other DEX implant trials.
Conclusions and place in therapy
There is significant morbidity associated with uveitis, spe-
cifically posterior uveitis which can account for 10% of 
cases of legal blindness in the United States. Corticosteroids 
remain the mainstay of treatment of all forms of uveitis but 
have significant adverse effects. The dexamethasone drug 
delivery system is a novel approach to the treatment of 
uveitis and has been shown to be efficacious in the treatment 
of noninfectious uveitis with potentially fewer adverse 
effects than other steroid moieties. As a result of recent 
clinical trials, the 0.7 mg dexamethasone sustained release 
intravitreal implant has been FDA approved for both the 
treatment of macular edema due to retinal vein occlusions 
and also for the treatment of noninfectious, posterior uveitis. 
Future studies will need to determine the relative efficacy 
and safety profiles among the different intravitreal steroid 
implants and the long-term effects of repeated use of the 
dexamethasone implant in the treatment of recurrent uveitis. 
Overall, the dexamethasone implant is an important new 
treatment modality and initial studies have demonstrated its 
efficacy with minimal adverse effects in the treatment of 
noninfectious uveitis.
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